Magnesium is the fourth most abundant mineral in the human body. It is a cofactor in over 300 enzymatic reactions — energy metabolism, DNA synthesis, muscle contraction, nerve conduction, blood pressure regulation, and insulin signalling. It is also, in 2025, the most searched mineral supplement globally. The search volume reflects a real clinical reality: deficiency is genuinely common, and the symptoms it produces — poor sleep, anxiety, muscle cramps, fatigue — are among the most frequently reported complaints in primary care.
How Common Is Deficiency — and Why
A 2024 analysis published in The Lancet Global Health estimated that approximately 2.4 billion people — roughly 31% of the global population — fail to meet recommended magnesium intake levels (Passarelli et al., 2024, Lancet Glob Health. 12:e1590–e1599). In the United States and Europe, national nutrition surveys consistently document inadequate intake in a large proportion of adults. The reasons are structural: magnesium is found primarily in whole grains, legumes, nuts, seeds, and dark leafy vegetables. Modern dietary patterns — refined grains, processed foods, low vegetable intake — systematically reduce exposure to these food groups. Certain medications further deplete magnesium status: proton pump inhibitors (PPIs), loop diuretics, and aminoglycoside antibiotics all increase renal magnesium excretion. Magnesium deficiency is widespread among patients with type 2 diabetes, with prevalence rates ranging from 13.5% to 47.7% in published studies, due to increased urinary losses from glycosuria.
One important clinical caveat: serum magnesium is an unreliable marker of true body status. Approximately 99% of total body magnesium is stored in bone, muscle, and soft tissue; only 1% circulates in serum. A normal serum magnesium result does not rule out intracellular or tissue-level deficiency — meaning standard blood tests may miss the majority of people who would benefit from supplementation.
Sleep — What the 2025 RCT Shows
The largest placebo-controlled RCT of magnesium supplementation for sleep published to date is Schuster et al. (2025), published in Nature and Science of Sleep (Nat Sci Sleep. 2025;17:2027–2040. DOI: 10.2147/NSS.S524348). It enrolled 155 healthy adults aged 18–65 years with self-reported poor sleep quality in a randomised, double-blind design comparing magnesium bisglycinate to matched placebo for 8 weeks. The magnesium bisglycinate group showed significant improvement in Insomnia Severity Index (ISI) scores versus placebo. There were no significant between-group differences in secondary outcomes including the Restorative Sleep Questionnaire, Fatigue Scale, or Perceived Stress Scale. No adverse events were reported and adherence was high.
A 2024 meta-analysis of three RCTs in older adults with insomnia (Mah and Pitre, BMC Complement Med Ther. 2024;24(1):418. DOI: 10.1186/s12906-024-04721-w) found that post-intervention sleep onset latency was 17.36 minutes less after magnesium supplementation compared to placebo (95% CI −27.27 to −7.44; p=0.0006). Total sleep time improved by 16.06 minutes but did not reach statistical significance. The authors noted that all three trials were at moderate-to-high risk of bias and outcomes were supported by low to very low quality of evidence per GRADE assessment. Their stated conclusion: the quality of literature is substandard for physicians to make well-informed recommendations on oral magnesium for older adults with insomnia.
A separate 2024 RCT of Magnesium L-threonate in adults with self-reported sleep problems (Hausenblas et al., Sleep Medicine X, collection date December 2024, PMC: 11381753) reported significant improvements in sleep quality scores versus placebo. The L-threonate form was selected for its proposed ability to cross the blood-brain barrier. This trial had a smaller sample than the Schuster bisglycinate trial.
What the data collectively support: magnesium supplementation, particularly bisglycinate or L-threonate form, shows a consistent positive signal for sleep quality in adults with self-reported poor sleep. The 17-minute reduction in sleep onset latency from the meta-analysis is statistically significant but modest in clinical magnitude. The 2025 bisglycinate trial (n=155) adds the most robust single-study evidence to date. Critical limitations across all trials include short durations (8–12 weeks maximum), heterogeneous populations, and predominantly subjective outcome measures rather than objective polysomnography.
Anxiety — What the 2024 Systematic Review Shows
Rawji et al. (2024) published a systematic review in Cureus examining the effects of supplemental magnesium on self-reported anxiety and sleep quality (Cureus. 2024;16(4):e59317. DOI: 10.7759/cureus.59317). Of 15 studies meeting inclusion criteria, seven reported anxiety-related outcomes. The majority of included studies reported that magnesium supplementation improved anxiety scores. Most used magnesium oxide at doses of 250–729 mg/day. The review concluded that supplemental magnesium is likely useful in the treatment of mild anxiety and insomnia, particularly in those with low magnesium status at baseline.
The limitations the authors explicitly identified matter clinically. Firm conclusions were limited by the heterogeneity of the data and the small participant numbers in most studies. Most studies assessed situational or heterogeneous anxiety — perioperative anxiety, postpartum anxiety — rather than generalised anxiety disorder as a primary diagnosis. Two studies reported negative results. The evidence is consistently positive in direction but does not yet meet the standard for clinical guideline recommendations for diagnosed anxiety disorders.
A 2023 meta-analysis of 7 RCTs in adults with depressive disorder (Moabedi et al., Front Psychiatry. DOI: 10.3389/fpsyt.2023.1333261; n=325) found a significant reduction in depression scores with magnesium supplementation (SMD: −0.919, 95% CI −1.443 to −0.396; p=0.001). Depression and anxiety frequently co-occur, and the neurological mechanisms proposed for magnesium — GABA-A receptor modulation, NMDA receptor antagonism — overlap between these conditions.
The Form Question — What Actually Changes
Not all magnesium supplements are equivalent. The compound magnesium is bound to determines absorption, gastrointestinal tolerance, and where in the body the magnesium concentrates. This is the most practically important consideration for clinical recommendation.
Magnesium oxide (MgO) has approximately 4% oral bioavailability. It is the cheapest form and appears in most low-cost multivitamins. For sleep, anxiety, or systemic magnesium repletion, oxide is an ineffective choice at standard doses — most passes through the gut unused. The 2024 Rawji systematic review noted that the one anxiety study reporting negative results was also the one using the lowest oxide dose (250 mg), suggesting both form and dose matter. Oxide's appropriate clinical use is as an osmotic laxative, where gut-level effect is the intention.
Magnesium bisglycinate has higher bioavailability than oxide and is the form used in the 2025 Schuster RCT — the largest sleep trial to date. The glycine component may contribute independently: glycine is an inhibitory neurotransmitter with its own sleep-promoting properties in human studies. Bisglycinate is well tolerated — the 2025 trial reported no adverse events. It is the most evidence-supported form for sleep and the most practical form for general supplementation.
Magnesium L-threonate (sold as Magtein) was developed to raise magnesium concentrations in the brain specifically. Animal studies showed L-threonate elevated cerebrospinal fluid magnesium by 7–15%, while other forms did not (Slutsky et al., 2010, Neuron). The human cognitive trial (Liu et al., 2016, J Alzheimers Dis; n=44 older adults with subjective memory complaints) reported improvements in executive function and working memory after 12 weeks at 1.5–2 g/day of the compound. This is a small, single-site, sponsor-associated study that has not been independently replicated in a larger trial. L-threonate delivers approximately 144 mg of elemental magnesium from 2 g of compound — less elemental magnesium per dose than glycinate at substantially higher cost. It is a reasonable choice for someone specifically targeting cognitive endpoints; it is not efficient for general repletion or as a primary sleep intervention.
Magnesium citrate offers good bioavailability at lower cost than glycinate and has a mild laxative effect at higher doses. For general supplementation without a specific sleep or cognitive focus, citrate is an appropriate and affordable option.
What the Evidence Does Not Establish
Several claims about magnesium circulate in supplement marketing that current evidence does not support at the level of clinical recommendation. Magnesium supplementation has not been shown to reduce cardiovascular events in a prospective RCT. Observational studies associate higher dietary magnesium intake with lower cardiovascular disease risk, but these are confounded by overall diet quality. Magnesium supplementation is not an antidiabetic intervention — deficiency is common in type 2 diabetes and correction may modestly improve insulin sensitivity in deficient individuals, but the effect size is small and the evidence base is thin compared to established antidiabetic treatments.
Most human sleep and anxiety trials have been conducted in magnesium-deficient or marginal-status populations. Whether supplementation produces the same benefits in people with adequate magnesium status has not been adequately studied. The most clinically plausible mechanism is deficiency correction — supplementation restoring normal physiological function — rather than a pharmacological effect above and beyond sufficiency. This matters for identifying who is likely to respond: people with poor dietary magnesium intake, those on PPIs or diuretics, people with type 2 diabetes, and heavy exercisers who lose magnesium through sweat are the most likely candidates.
Practical Summary
The evidence for magnesium and sleep is the strongest and most recent: the 2025 bisglycinate RCT (n=155) is the largest placebo-controlled trial published in this area and showed significant ISI improvement with no adverse events. The 2024 meta-analysis showing 17-minute reduction in sleep onset latency (p=0.0006) provides statistically significant if modest support. For sleep, recommend magnesium bisglycinate or magnesium citrate at approximately 300–400 mg elemental magnesium per day taken with food in the evening. Avoid recommending magnesium oxide for this indication. For anxiety, the 2024 Rawji systematic review supports use for mild anxiety particularly in those with low baseline magnesium status, but the evidence does not yet support recommendation for diagnosed generalised anxiety disorder. Serum magnesium testing is an unreliable guide to clinical decision-making — a dietary history focused on whole grain, legume, nut, and vegetable intake is more informative for identifying likely responders.
References
- Schuster J, Kretschmer M, Smolka JN, et al. (2025). Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 17:2027-2040.
- Rawji A, Peltier MR, Mourtzanakis K, Awan S, Rana J, Pothen NJ, Afzal S. (2024). Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review. Cureus. 16(4):e59317.
- Mah J, Pitre T. (2024). Oral magnesium supplementation for insomnia in older adults: a Systematic Review and Meta-Analysis. BMC Complement Med Ther. 24(1):418.
- Hausenblas HA, Lynch T, Hooper S, Hooper D, Spar M, Bedfortune N. (2024). Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep Med X. Dec 2024. PMC11381753.
- Moabedi M, Aliakbari M, Erfanian S, Milajerdi A. (2023). Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Front Psychiatry. 14:1333261.
- Passarelli S, Free CM, Shepon A, et al. (2024). Global estimation of dietary micronutrient inadequacies: a modelling analysis. Lancet Glob Health. 12:e1590-e1599.
- Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S. (2016). Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis. 49(4):971-990.
- Slutsky I, Abumaria N, Wu LJ, et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron. 65(2):165-177.